Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ILOSONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ILOSONE.
ERYC vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic